Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma
| Autor: | Jane N. Winter |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Ibritumomab tiuxetan Iodine I 131 Tositumomab Hematopoietic stem cell transplantation Transplantation Autologous Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Combined Modality Therapy Yttrium Radioisotopes CD20 Clinical Trials as Topic biology business.industry Lymphoma Non-Hodgkin Antibodies Monoclonal Radioimmunotherapy Antigens CD20 Transplantation Immunology biology.protein business Stem Cell Transplantation medicine.drug |
| Zdroj: | Clinical Lymphoma. 5:S22-S26 |
| ISSN: | 1526-9655 |
| DOI: | 10.3816/clm.2004.s.005 |
| Popis: | Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect